MIV-828 is a nucleotide-based prodrug optimized for the treatment of acute myeloid leukemia (AML) and other forms of blood cancer (including myelodysplastic syndrome (MDS) and T-cell lymphoma). Acute myeloid leukemia (AML) occurs when cells in the bone marrow that are intended to develop into normal white blood cells instead become cancer cells. These cancer cells accumulate in the bone marrow and prevent the development of normal blood cells.
In the US, around 20,000 people per year are estimated to be diagnosed with AML. The risk of being affected increases with increasing age. The average five-year survival among patients diagnosed with AML was approximately 28 percent during the 2009-2015 period (National Cancer Institute). The prognosis is poor for a large proportion of patients, as the intensive treatment currently used to treat the disease is not tolerated. The fact that patients relapse in disease after treatment is common and the remaining treatment alternatives are then limited.
MIV-828 is designed to overcome the resistance mechanisms that can inhibit the effects of other nucleoside analogues, such as cytarabine, currently used for the treatment of AML. Preclinical data indicate that MIV-828 may offer patients with AML and other blood cancers a treatment with better tolerability and efficacy. In preclinical studies, MIV-828 exhibits activity in AML with varying genetic background (mutations), which could support broad use. MIV-828 is developed to be combined with other treatments and exhibits synergistic anti-cancer activity in combination therapy in preclinical models.
In November 2018, Medivir’s proprietary substance MIV-828 was selected as a candidate drug. MIV-828 is a nucleotide-based prodrug optimized for the treatment of acute myeloid leukemia (AML) and other forms of blood cancer (including myelodysplastic syndrome (MDS) and T-cell lymphoma). Next step in the development of MIV-828 is to conduct the preclinical safety studies to enable us to start the first clinical studies.